hepatitis A virus infection
diseaseOn this page
Also known as Hepatitis AHepatitis A infectionhepatitis type A
Summary
hepatitis A virus infection (MONDO:0005790) is a disease and 74 clinical trials. Top therapeutic interventions include hepatitis b virus hbsag surface protein antigen, ursodiol, and aldesleukin. A subtype of viral hepatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 74
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | hepatitis A virus infection |
| Mondo ID | MONDO:0005790 |
| EFO | EFO:0007305 |
| MeSH | D006506 |
| DOID | DOID:12549 |
| NCIT | C3096 |
| SNOMED CT | 40468003 |
| UMLS | C0019159 |
| MedGen | 42418 |
| Is cancer (heuristic) | no |
Also known as: Hepatitis A · Hepatitis A infection · hepatitis type A
Data availability: 6 cell lines.
Disease family
This is a subtype of viral hepatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › hepatitis › viral hepatitis › hepatitis A virus infection
Related subtypes (5): Epstein-Barr virus hepatitis, hepatitis C virus infection, hepatitis B virus infection, hepatitis E virus infection, hepatitis D virus infection
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Hepatitis B Virus Hbsag Surface Protein Antigen | Approved (phase 4) |
| Typhoid Vi Polysaccharide Vaccine | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Honey, Silybin A.
Clinical trials & evidence
Clinical trials
Clinical trials: 74.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE4 | 30 |
| PHASE3 | 20 |
| Not specified | 17 |
| PHASE2 | 4 |
| PHASE2/PHASE3 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06058416 | PHASE4 | ACTIVE_NOT_RECRUITING | Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old |
| NCT06460545 | PHASE4 | NOT_YET_RECRUITING | Phase IV Study of Concomitant Administration of the sIPV and HepA |
| NCT00139113 | PHASE4 | COMPLETED | Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children |
| NCT00289731 | PHASE4 | COMPLETED | Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc |
| NCT00289757 | PHASE4 | COMPLETED | Long-Term Immune Persistence of GlaxoSmithKline Biologicals’ Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule |
| NCT00291876 | PHASE4 | COMPLETED | Long-Term Immune Persistence of GlaxoSmithKline Biologicals’ Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule |
| NCT00313950 | PHASE4 | COMPLETED | Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine |
| NCT00326183 | PHASE4 | COMPLETED | Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) |
| NCT00534885 | PHASE4 | COMPLETED | Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine |
| NCT00603252 | PHASE4 | COMPLETED | Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults |
| NCT00684671 | PHASE4 | COMPLETED | Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination |
| NCT00875485 | PHASE4 | COMPLETED | Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™ |
| NCT01000324 | PHASE4 | COMPLETED | Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult |
| NCT01037114 | PHASE4 | COMPLETED | Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult |
| NCT01252680 | PHASE4 | COMPLETED | Immunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines |
| NCT01341808 | PHASE4 | COMPLETED | Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients |
| NCT01349829 | PHASE4 | COMPLETED | A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children |
| NCT01865968 | PHASE4 | COMPLETED | Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults |
| NCT01949857 | PHASE4 | COMPLETED | The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines |
| NCT02011763 | PHASE4 | COMPLETED | Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents |
| NCT02124785 | PHASE4 | WITHDRAWN | Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals’ Hepatitis A Vaccine, Havrix® |
| NCT02135666 | PHASE4 | WITHDRAWN | Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals’ Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084) |
| NCT02445703 | PHASE4 | COMPLETED | Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine |
| NCT02601040 | PHASE4 | COMPLETED | Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines |
| NCT03183492 | PHASE4 | WITHDRAWN | Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals’ Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel |
| NCT03231605 | PHASE4 | UNKNOWN | Comparative Immunogenicity Study of Two Hepatitis A Vaccines |
| NCT03330171 | PHASE4 | UNKNOWN | Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine |
| NCT03855176 | PHASE4 | COMPLETED | Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients |
| NCT06184230 | PHASE4 | UNKNOWN | Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination. |
| NCT06576024 | PHASE4 | COMPLETED | Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People |
| NCT06978621 | PHASE3 | ACTIVE_NOT_RECRUITING | Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV |
| NCT00119743 | PHASE3 | TERMINATED | A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine |
| NCT00197002 | PHASE3 | COMPLETED | Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age |
| NCT00197015 | PHASE3 | COMPLETED | Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children |
| NCT00197119 | PHASE3 | COMPLETED | Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years |
| NCT00197171 | PHASE3 | COMPLETED | Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine |
| NCT00197184 | PHASE3 | COMPLETED | Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared |
| NCT00197236 | PHASE3 | COMPLETED | Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months |
| NCT00197249 | PHASE3 | COMPLETED | Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity |
| NCT00289718 | PHASE3 | COMPLETED | Long-Term Immune Persistence of GSK Biologicals’ Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN | 4 | 2 |
| URSODIOL | 4 | 2 |
| ALDESLEUKIN | 4 | 1 |
| HONEY | 3 | 1 |
| LACTOSE MONOHYDRATE | 3 | 1 |
| SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN | 3 | 1 |
| SILIBININ | 3 | 1 |
| SILYBIN A | 3 | 1 |
| CHEMBL5308485 | 0 | 1 |
| CHEMBL5409583 | 0 | 1 |
| SILYBIN B | 0 | 1 |
| SILYMARIN | 0 | 1 |